Fig. 5

Difference between dual therapy vs. monotherapy in the risk of developing adverse events. CI confidence interval, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist